Hamza Suria - Nov 1, 2021 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Role
President, CEO, Director
Signature
/s/ Eric Loumeau, Attorney-in-Fact
Stock symbol
ANAB
Transactions as of
Nov 1, 2021
Transactions value $
-$1,143,063
Form type
4
Date filed
11/2/2021, 05:53 PM
Previous filing
Oct 28, 2021
Next filing
Nov 5, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANAB Common Stock Options Exercise $41K +36.6K +54.18% $1.12* 104K Nov 1, 2021 Direct
transaction ANAB Common Stock Sale -$1.1M -34.1K -32.69% $32.27 70.2K Nov 1, 2021 Direct F1, F2
transaction ANAB Common Stock Sale -$84.1K -2.56K -3.65% $32.88 67.6K Nov 1, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANAB Employee Stock Option (right to buy) Options Exercise $0 -36.6K -50% $0.00 36.6K Nov 1, 2021 Common Stock 36.6K $1.12 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.84 to $32.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.85 to $32.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F4 The stock option grant was issued on January 31, 2012 and became fully vested as of January 31, 2016, and is exercisable until its expiration date of January 31, 2022.
F5 In addition to the remaining options to purchase 36,645 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,139,254 shares of common stock, which options vest according to their terms, and (ii) 67,636 shares of common stock held directly.